AiViva BioPharma Press Release May 22, 2023
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 (globenewswire.com)
top of page
Search
全球汽車電裝配備大廠輝創電子 5/11興櫃掛牌
https://tw.stock.yahoo.com/news/%E5%85%A8%E7%90%83%E6%B1%BD%E8%BB%8A%E9%9B%BB%E8%A3%9D%E9%85%8D%E5%82%99%E5%A4%A7%E5%BB%A0%E8%BC%9D%E5%89...
兆聯實業(6944)4/27起開始興櫃一般板買賣
https://jdata.yuanta.com.tw/z/zu/zub/zubb/zubba/zubbaz/zubbaz.djhtm?A=ASR6944&B=57BF868A-1397-4438-A5ED-06C728E777DC
創控科技(6909)將於3/30掛牌興櫃交易
創控3/30掛興櫃！打入台積電等半導體供應鏈、6年維持逾5成高毛利：未來營運樂觀期待 (yahoo.com)
益得複方吸入劑在台上市銷售 同步擴大海外布局
https://www.taiwan-healthcare.org/zh/news-detail?id=0rtnd87r8wslyezf&utm_source=line&utm_medium=b2b&utm_campaign=dailynews_0425
Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Capability
NULISA: a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing | bioRxiv
The Top 3 Future Foods at CES 2023
The Top 3 Future Foods I Tasted At CES 2023 (greenqueen.com.hk)
Eureka Therapeutics is selected 2022 Red Herring Top 100 Global Winners
https://smex-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fwww.redherring.com%2fevents%2fred%2dherring%2dglobal%2f2022%...
〈視陽光學轉上市〉檳城廠持續擴充 明年Q2月產能上看3800萬片增逾2成
https://news.cnyes.com/news/id/4988977?utm_campaign=share_button&utm_medium=news_article&utm_source=cnyesnewsapp
Botrista raises $55M, hires former Zoup president to lead strategy
https://www.fastcasual.com/news/botrista-raises-55m-hires-former-zoup-president-to-lead-strategy/
SPAC熱潮再起！+創新T細胞療法公司Estrella上市+估值近4億美元 - 環球生技月刊
https://news.gbimonthly.com/tw/article/show.php?num=53575
永聯物流開發旗下「艾立運能」完成 A 輪募資，布局上中游網路、擴增冷鏈運輸」
https://technews.tw/2022/09/13/ally-transport-system-series-a-financing/
Lypid teams up with Louisa Coffee to launch plant based hamburger
路易莎「未來肉」肉汁全靠他！29歲台大學霸如何靠Linkedin在美募到1億元創業？ https://www.cw.com.tw/article/5122458?utm_campaign=line_-website_share-icon&utm_medium=website...
BMS acquisition of Turning Point Therapeutics at US$4.1 B closed on 8/15/2022
https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-and-Turning-Point-Therapeutics-Announce-Expiration-of-HSR-Act-Waiting-Period-...
Applied Biocode is selected top 10 leading molecular diagnostics cos to watch in 2022 by C10 Insight
專題完整報導 https://cioinsights.com/?r3d=top-10-leading-molecular-diagnostics-companies-to-watch-in-2022 採訪瑞磁 https://cioinsights.com/applied-...
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response...
逸達前列腺癌新劑型新藥 CAMCEVI 42 毫克獲加拿大上市許可
（2021 年 11 月 18 日，臺北訊）逸達生技（6576.TWO，簡稱逸達）今日宣布，接獲授權夥伴 Accord Healthcare 通知，加拿大衛生部 Health Canada 已核可前列腺癌新劑型新藥 CAMCEVI 42 毫 克的新藥上市申請。...
Alamar Biosciences Completes $80M Series B Fundraising to Bring UnprecedentedPerformance to the Pro
Fremont, CA, September 8, 2021 (PR NEWSWIRE) -- Alamar Biosciences, Inc., a precision proteomics company that brings both ultra-high...
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
Jun 17, 2021 SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology...
EUREKA THERAPEUTICS ANNOUNCES INITIATION OF PHASE I/II ARYA-3 CLINICAL TRIAL OF GPC3 TARGETING ARTEM
Emeryville, California, July 21, 2021 -- Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell...
bottom of page